BUENA PARK, CA–(Marketwire – February 8, 2012) – SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceuticals, nutraceutical and dermatology company that manufactures and markets generic drugs covering all major treatment categories, today announced its financial result for 4th quarter and fiscal year 2011.

Revenues for the fourth quarter, period ending December 31, 2011 were $530,989, an increase of $391,726, or a 381% increase, as compared to the same period last year. Net loss for the quarter was $52,220, as compared to a net loss of $280,886 for the same period last year. The bottom line results improved 252% as compared to the same period last year.

Revenues for the full year 2011 were $1,349,341, an increase of $567,666, or a 72% increase as compared to 2010 revenues. Net loss for fiscal year 2011 was $548,990, as compared to a net loss of $980,457 for fiscal year 2010. The bottom line results for 2011 improved 44% as compared to fiscal year 2010.

Mr. Shailesh Shah, CEO of SOHM Inc., stated, “We continue to make significant improvements in our top and bottom line results and believe our infrastructure, combined with our sales and marketing plans will continue to provide very good results. Last year we made strategic changes in our systems, including distribution channels and became very aggressive towards new product and new market launches, all of which provided our customers with better service and allowed us to streamline operations and control expenses.”

“We are focusing our business plan on profitability by continuing to expand operations and partnerships, but ensuring that our expenses are in line with gross profit margins,” concluded Mr. Shah.

About SOHM, Inc.

SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement:

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:

Andrew Barwicki

SOHM, Inc.

Investor Relations

(714) 522-6700

With the launch of these additional products, SOHM product lines now include: dry dermatoses, mixed skin infection, acne vulgaris, seborrhic dermatitis, and cuts, wounds and burns products. With these products, SOHM is expected to increase overall revenues by approximately 55 to 60%.

Mr. Shailesh Shah, President and CEO, said in his statement today that Sohm Dermatology division has a structured strategy of capturing every subdivision within the Dermatology segment. In the first phase, after takeover, Sohm derma re-launched six products into the Indian subcontinent focused on Dry SRDs (Dry Steroid Responsive Dermatomes) offering alternatives for unmet needs and aiding in the armamentarium of Dermatologists.

These four different strengths of unique formulations would allow Dermatologists to deal with acute eczema, recalcitrant psoriasis, palmer, planter keratosis and various chronic dry dermatoses. These formulations, Soria-3, Soria-6, Keratomax and Salic-12 share a unique spectrum of indications all covered under Dry Dermatoses, making the task of dermatologists that much easier for both dramatic results as well as systematic resolution for patients benefits.

In addition to Dry SRDs, Sohm Derma also introduced two unique face wash products, in both Salic-2 Gel as well as Salic-2 Foam especially in the management of acne vulgaris, as well as general purpose medicated face wash. Salic-2 Gel, due to its unique base, ensures effective exfoliation to restore normal pH of the skin. It dissolves blackheads, and prevents formation of white heads. For oily skin Slaic-2 gel and for dry skin Salic-2 Foam, are an effective product mix, thus Sohm Derma not only captures the spectrum of patient requirements but also fulfills Dermatologists’ options to deliver a variety of solutions to skin ailments.

Sohm derma field force is making significant investments in the mindset of Dermatologists so eventually it can capture the shelf space of pharmacists’ retails outlets. Sohm Derma approaches the marketing with a unique set of methods, systems and processes.

Further Mr. Shailesh Shah, announced that in the Second Phase, Sohm Derma is launching five more products by February 2012, which would deal with mixed skin infection, acne vulgaris, seborrhic dermatitis, and cuts, wounds and burns products. With a unique combination and applied innovation, Sohm Derma can diligently make inroads into the mindset of Dermatologists as well as General practitioners, and make an impact even against established brand leaders, and emerge as a major challenger in brand wars.

The five products include Mixona-3 for Mixed skin infections, Noyte for Dandruff, Acnobenz 2.5 & Acnobenz 5 for acne vulgaris, and Silconan-4 a unique combination of silver suphadiazine with chlorhxidine glucoante 4% which is a more powerful bactericidal in cuts, wounds, and localized burns than any in its category.

It challenges both antibacterial as well as anti-burn brand leaders. Acnobenz reinforces Salic-2 Range, Noyte strengthens Dry SRDs range, and Silconan-4 actually builds a unique brand leader and will set the example for others to follow.

Sohm anticipates that its innovation will eventually begin to lead in all major therapeutic segments of dermatology, be it Dry SRDs, Acne Management or cuts, wounds and localized burns.

Mr. Shah is confident that these two phases of product rollout can easily exceed our revenue goals out of all eleven products for the year 2012, and said it will make at least 3-4 brands paving the way to make Sohm a nascent force to reckon with in Dermatology within India, and eventually in the international market.

The Indian pharmaceutical market is currently valued at USD 10 billion. It is one of the fastest growing pharmaceutical markets in the world and is forecasted to grow in double-digits in medium term. The Indian dermatology market, valued at USD 513 million, grew by 21% in 2010 and represents 25% of the Asia-Pacific dermatology market with a CAGR of 15% (2005-2010) and is a significant growth driver of the Indian pharmaceutical market.

Finally Mr. Shah is confident that SOHM’s dermatology, nutraceutical and generic pharmaceutical operations, the company will be able to expand and enhance distribution channels that will add to revenues and profitability in 2012.

We anticipate that unaudited Year End 2011 Revenue will be released by February 7th, 2012.

As previously stated in our press release dated 11/03/2011:

“The company generated net revenues of $448,607 for the three months ended September 30, 2011, as compared to $102,543 for the same period last year, which represents a 337% increase. Gross profit for the quarter was $282,042, as compared to $53,498 for the same period last year.”

“For the nine months ended September 30, 2011, revenues were $809,352, as compared to $642,412 for the nine months ended in 2010, which represents a 26% increase. Gross profit for the nine months ended September 30, 2011 were $296,752, as compared to $232,407 for the same period last year. Net loss for the nine months ended September 30, 2011 was $496,770, as compared to a net loss of $739,571 for the same period last year.”

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical, nutraceutical and dermatology manufacturer that produces and markets pharmaceuticals and nutraceutical drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement:
This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact
Investor Relations
Andrew Barwicki
714-522-6700

SOHM takes steps to build momentum

BUENA PARK, CA– (01/18/2012) – SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announced its Nutraceutical plant have been operational and has commenced commercial production since last month.

Mr. Shailesh Shah, President and CEO said that he is very pleased to announce that last month SOHM’s in-house neutraceutical plant commenced its commercial production of neutraceutical product lines, including Diorac, a unique probiotic anti–diarrheal product. The in house manufacturing plant helps to extend SOHM’s core competence to include neutraceutical at a right time when the United States Food & Drug Administration and the Indian Food & Drug Administration are simplifying regulations in regard to neutraceutical deliverables. We believe these changes and adjustments to the regulations will allow SOHM to more quickly and effectively reach millions of consumers more cost effectively.

Mr. Shah added that SOHM’s new plant, which is located near the company’s India headquarters in Ahmedabad, is in compliance with all Dietary Supplement Health and Education Guidelines. Furthermore the company has received an endorsement and necessary regulatory compliances with local authority as well as with the Indian Food & Drug Administration and Food Standards Authority of India.

As the medicine moves away from palliative and diagnostic paradigm into curative and proactive regiments, neutraceuticals increasingly are seen as a core component in healthy lifestyle management worldwide. To that end SOHM’s organizational competencies will increasingly be deemed to meet growing and evolving market opportunities in the neutraceutical segment, Mr. Shailesh Shah added.

Finally Mr. Shah said in his message that with the commencement of production at the neutraceutical facility, SOHM has reached two milestones. First, SOHM’s pipeline of new and innovative products is now guaranteed. Secondly, when combined with SOHM’s dermatology and generic pharmaceutical operations, the company will be able to expand and enhance distribution channels that will add to revenues and profitability in 2012.

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact
Investor Relations

Andrew Barwicki

516-662-9461 / 714-522-6700

BUENA PARK, CA– (11/23/2011) – SOHM, Inc. (PINKSHEETS: SHMN), a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories, today announces the acquisition of business and brands of privately owned Novatrend Medicament Pvt. Ltd.

Shailesh Shah, President and CEO of SOHM, Inc. stated, “We are very pleased to announce this acquisition and believe it is an important strategic move for SOHM, expanding our presence in the rapidly growing pharmaceutical market. After a thorough due diligence process and proper financing arrangements, we have completed the previously announced acquisition of the tangible and intangible assets, rights and technical intellectual property and formulation of all the products of Novatrend Medicament Pvt. Ltd. This acquisition will bring in a range of Dermatology and Cosmeceutical products to the product portfolio of SOHM, Inc.”

“Within the existing 17 products from Novatrend, there are 6 products that were new to the Indian market. Furthermore, there are 40 more new products that are in the pipeline in coming years. Along with the new product range Novatrend is also bringing its sales network in 7 states with 120 established distributors and stockists. Revenue expectations include an additional $1.5 million to the existing revenue of SOHM, Inc. during the fiscal year of 2012, all of which will allow the company to achieve its revenue and profitability goals for 2012 and beyond,” concluded Mr. Shah.

Mr. Sanjiv Bosamia of Novatrend, a pharmaceutical veteran has been appointed as CEO of SOHM’s newly acquired Dermatology and Cosmeceutical division. His vision and nearly 30 years of experience in the field of pharmaceuticals with special focus on dermatology and cosmeceuticals will bring in strong leadership and guidance to the division and the company. This will further help the company in achieving its goal of transitioning from generic drugs to innovative & knowledge based products.

The Indian pharmaceutical market is currently valued at USD 10 billion. It is one of the fastest growing pharmaceutical markets in the world and is forecasted to grow in double-digits in medium term. The Indian dermatology market, valued at USD 513 million, grew by 21% in 2010 and represents 25% of the Asia-Pacific dermatology market with a CAGR of 15% (2005-2010) and is a significant growth driver of the Indian pharmaceutical market.

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:
Investor Relations

Andrew Barwicki

714-522-6700

Shailesh Shah, President and CEO of SOHM, Inc. stated, “We believe video communication for current and prospective investors is an effective marketing and investor relations tool because they can see the face behind the message. I am excited to have initiated the video messaging as the technologically has become more advanced, and provides a personal medium in which we can provide confidence to the investment community. We expect to give video updates to the investment community for all new important developments and announcements.

About SOHM, Inc.
SOHM, Inc. is a generic pharmaceutical manufacturer that produces and markets generic drugs covering all major treatment categories. Global headquarters is located in North America with manufacturing sites in India. Generic pharmaceuticals are exported globally with a focus on distribution in emerging markets in Africa, Latin America, and Southeast Asia. www.sohm.com

Safe Harbor Statement

This press release contains statements, which may constitute “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of SOHM, Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

For more information, please contact:
Investor Relations

Andrew Barwicki

714-522-6700